EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (GlobeImmune)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameEGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (GlobeImmune)
Drug Alias NameGlioVax-1GI-3001GI-3000GI-6200
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlobeimmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlobeimmune Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungBrain Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A